These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 16850274)

  • 1. Ligand-targeted delivery of therapeutic siRNA.
    Ikeda Y; Taira K
    Pharm Res; 2006 Aug; 23(8):1631-40. PubMed ID: 16850274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4-targeted modular peptide carriers for efficient anti-VEGF siRNA delivery.
    Egorova A; Shubina A; Sokolov D; Selkov S; Baranov V; Kiselev A
    Int J Pharm; 2016 Dec; 515(1-2):431-440. PubMed ID: 27789364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual antitumoral potency of EG5 siRNA nanoplexes armed with cytotoxic bifunctional glutamyl-methotrexate targeting ligand.
    Lee DJ; Kessel E; Edinger D; He D; Klein PM; Voith von Voithenberg L; Lamb DC; Lächelt U; Lehto T; Wagner E
    Biomaterials; 2016 Jan; 77():98-110. PubMed ID: 26584350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient and targeted delivery of siRNA in vivo.
    Shim MS; Kwon YJ
    FEBS J; 2010 Dec; 277(23):4814-27. PubMed ID: 21078116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring cell type-specific internalizing antibodies for targeted delivery of siRNA.
    Liu B
    Brief Funct Genomic Proteomic; 2007 Jun; 6(2):112-9. PubMed ID: 17670766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for in vivo siRNA delivery in cancer.
    Sanguino A; Lopez-Berestein G; Sood AK
    Mini Rev Med Chem; 2008 Mar; 8(3):248-55. PubMed ID: 18336345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla.
    Meade BR; Dowdy SF
    Discov Med; 2009 Dec; 8(43):253-6. PubMed ID: 20040280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoprotein-Mediated siRNA Delivery.
    Bäumer N; Berdel WE; Bäumer S
    Mol Pharm; 2017 May; 14(5):1339-1351. PubMed ID: 28170265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells.
    Dong DW; Xiang B; Gao W; Yang ZZ; Li JQ; Qi XR
    Biomaterials; 2013 Jul; 34(20):4849-59. PubMed ID: 23541420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic face of RNAi: in vivo challenges.
    Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S
    Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system.
    Kim SW; Kim NY; Choi YB; Park SH; Yang JM; Shin S
    J Control Release; 2010 May; 143(3):335-43. PubMed ID: 20079391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA interference therapeutics for cancer: challenges and opportunities (review).
    Bora RS; Gupta D; Mukkur TK; Saini KS
    Mol Med Rep; 2012 Jul; 6(1):9-15. PubMed ID: 22576734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.
    Dou S; Yao YD; Yang XZ; Sun TM; Mao CQ; Song EW; Wang J
    J Control Release; 2012 Aug; 161(3):875-83. PubMed ID: 22762887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving siRNA bio-distribution and minimizing side effects.
    Scaggiante B; Dapas B; Farra R; Grassi M; Pozzato G; Giansante C; Fiotti N; Grassi G
    Curr Drug Metab; 2011 Jan; 12(1):11-23. PubMed ID: 21222588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To Conjugate or to Package? A Look at Targeted siRNA Delivery Through Folate Receptors.
    Salim L; Desaulniers JP
    Nucleic Acid Ther; 2021 Feb; 31(1):21-38. PubMed ID: 33121373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design and exogenous delivery of siRNA for post-transcriptional gene silencing.
    Gilmore IR; Fox SP; Hollins AJ; Sohail M; Akhtar S
    J Drug Target; 2004 Jul; 12(6):315-40. PubMed ID: 15545082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical and structural modifications of RNAi therapeutics.
    Ku SH; Jo SD; Lee YK; Kim K; Kim SH
    Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.